| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | G Selivanova | |
| K G Wiman | |||
| V J N Bykov | |||
| P2860 | cites work | The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. | Q53390021 |
| Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene | Q73100618 | ||
| Pharmacological rescue of mutant p53 conformation and function | Q73316566 | ||
| Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | Q73400021 | ||
| The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU | Q78553738 | ||
| ASPP proteins specifically stimulate the apoptotic function of p53 | Q24291844 | ||
| Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 | Q24314736 | ||
| A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | Q24530763 | ||
| Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells | Q24796572 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Surfing the p53 network | Q28032484 | ||
| Rescuing the function of mutant p53. | Q30329984 | ||
| Solubility as a function of protein structure and solvent components | Q30334367 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. | Q34740058 | ||
| Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. | Q39445499 | ||
| The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein | Q40711276 | ||
| Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. | Q40747748 | ||
| An information-intensive approach to the molecular pharmacology of cancer. | Q41134023 | ||
| The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. | Q42806263 | ||
| Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. | Q43955939 | ||
| Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. | Q44266870 | ||
| Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. | Q44380836 | ||
| Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. | Q52247619 | ||
| Protein folding and disease: a view from the first Horizon Symposium. | Q53356760 | ||
| P433 | issue | 13 | |
| P304 | page(s) | 1828-1834 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Small molecules that reactivate mutant p53. | |
| P478 | volume | 39 |
| Q28472376 | Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70 |
| Q36226739 | Apoptotic pathways and therapy resistance in human malignancies |
| Q39226379 | Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. |
| Q36173604 | CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice |
| Q35804653 | Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. |
| Q104795043 | Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway |
| Q42088464 | Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants |
| Q35850522 | Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action |
| Q51186530 | Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. |
| Q33756254 | Expression and functional characterization of platelet-derived growth factor receptor-like gene |
| Q30377322 | Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database. |
| Q42142504 | Identification of a small molecule 1,4-bis-[4-(3-phenoxy-propoxy)-but-2-ynyl]-piperazine as a novel inhibitor of the transcription factor p53. |
| Q38089906 | Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins |
| Q37183461 | Molecular pathology and potential therapeutic targets in soft-tissue sarcoma |
| Q33755827 | Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells |
| Q40362071 | Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis |
| Q41968106 | Mutant p53 targeting by the low molecular weight compound STIMA-1 |
| Q37445903 | Novel HIV-1 therapeutics through targeting altered host cell pathways |
| Q37826349 | Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors |
| Q44327720 | P53 family proteins provide new insights into lung carcinogenesis and clinical treatment |
| Q46458121 | PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. |
| Q30486972 | PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. |
| Q37689194 | Patented small molecule inhibitors of p53-MDM2 interaction |
| Q37137255 | Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment |
| Q33503650 | Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning |
| Q24813658 | Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells |
| Q44145204 | QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants |
| Q40401654 | Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q37481259 | Sirtuin inhibitors. |
| Q37449030 | Specifically targeted gene therapy for small-cell lung cancer. |
| Q36430162 | Strategies for therapeutic targeting of the p53 pathway in cancer. |
| Q35127734 | Structural basis for understanding oncogenic p53 mutations and designing rescue drugs |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q35979294 | TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death |
| Q40085524 | The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. |
| Q36425978 | The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation. |
| Q36430748 | The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer |
| Q40186188 | The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis |
| Q36501370 | Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease |
| Q28389231 | Tumor suppressor and hepatocellular carcinoma |
| Q33511752 | p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype |
| Q37242078 | p53 as a therapeutic target. |
| Q24338379 | p53: 25 years after its discovery |
Search more.